They accomplished this by utilizing both a CAV-1 overexpression plasmid and siRNA and demonstrated that AS-IV suppresses the expression of CAV-1 and stimulates the endothelial nitric oxide synthase/nitric oxide pathway, thereby enhancing the chemical responsiveness of breast cancer to paclitaxel. The gene discussed is CAV1; the disease is breast carcinoma.